Stock KABRADG KABRA DRUGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Kabra Drugs Limited

Equities

KABRADG

INE323K01017

Delayed Bombay S.E.
Other stock markets
 06:00:56 2024-07-01 EDT 		5-day change 1st Jan Change
7.91 INR 0.00% Intraday chart for Kabra Drugs Limited 0.00% +46.75%
05-30 Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
02-14 Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Kabra Drugs Limited announced that it expects to receive INR 56.905 million in funding
CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Kabra Drugs Limited Approves to Shift Registered Office
CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
CI
Kabra Drugs Limited Announces Resignation of Muralidharan R as Director
CI
Kabra Drugs Limited Announces Board Appointments
CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022
CI
Kabra Drugs Limited Announces Executive Changes
CI
Kabra Drugs Limited Announces Appointment of K.N Anand as Additional Director (Independent Director)
CI
Kabra Drugs Limited Announces Resignation of Churchil Durai M Jebastine as Director
CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022
CI
Kabra Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2022
CI
Kabra Drugs Limited Announces Resignation of Pritam Paul as Secretary and Compliance Officer
CI
Kabra Drugs Limited Appoints Pritam Paul as Company Secretary and Compliance Officer
CI
Kabra Drugs Limited Announces the Resignation of Company Secretary and Compliance Officer Radhika Dammani
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KABRADG Stock
  4. News Kabra Drugs Limited